For those who had CRS-HIPEC but still have residual disease, what treatments have you tried afterward? I had a...

Post-CRS-HIPEC Treatment Options for Residual Appendiceal Cancer

I understand you're navigating a challenging situation with residual disease after extensive CRS-HIPEC surgery. Let me address each of your questions systematically, though I need to be transparent that my knowledge base has limited specific information about post-CRS-HIPEC treatments for appendiceal cancer.

1) Ibrance (Palbociclib) After CRS-HIPEC

What I Found: I don't have specific research on Ibrance use after CRS-HIPEC for appendiceal cancer in my knowledge base. The small study your oncologist mentioned (16 patients) represents emerging evidence that isn't yet widely documented in standard guidelines.

What This Means:

• CDK4/6 inhibitors like Ibrance work by blocking proteins that help cancer cells divide
• They're FDA-approved for certain breast cancers but are being explored "off-label" for other cancers
• Small studies can show promise, but limited data means less certainty about effectiveness and side effects in your specific situation

Questions to Ask Your Oncologist:

1. Can you share the published study or data on Ibrance for appendiceal cancer?
2. What response rate was seen in those 16 patients?
3. What were the most common side effects in that study?
4. How will we monitor whether it's working (tumor markers, imaging schedule)?
5. What's the plan if Ibrance doesn't control the disease?
6. Are there any molecular features of my tumor (like hormone receptors) that suggest I might respond?

2) Chemotherapy Regimens After CRS-HIPEC

What I Found: My knowledge base contains limited specific information about systemic chemotherapy protocols used after CRS-HIPEC for appendiceal cancer with residual disease.

General Context: For appendiceal cancers, chemotherapy options may include:

• 5-FU based regimens (like FOLFOX or FOLFIRI) - commonly used for colorectal and appendiceal cancers
• Capecitabine (oral chemotherapy) - sometimes used for maintenance
• The choice often depends on:
  • Your tumor's histology (mucinous features)
  • Prior treatments received
  • Your overall health and tolerance

Questions to Ask Your Oncologist:

1. Which specific chemotherapy regimen are you recommending and why?
2. What's the expected response rate for this regimen in appendiceal cancer with residual disease?
3. What's the treatment schedule (how often, for how long)?
4. What are the most common side effects I should prepare for?
5. How will we know if it's working (monitoring schedule)?
6. Is this intended as disease control or potentially curative?
7. What's the typical duration of benefit seen with this approach?

3) Side Effects: Ibrance vs. Chemotherapy

Ibrance (CDK4/6 Inhibitor) - Typical Side Effects:

• Most common: Low blood counts (especially neutropenia - low white blood cells)
• Fatigue
• Nausea
• Mouth sores
• Hair thinning (usually less severe than traditional chemo)
• Generally considered better tolerated than traditional chemotherapy

Low-Intensity Chemotherapy - Side Effects Vary By Regimen:

• Fatigue
• Nausea/vomiting
• Diarrhea or constipation
• Neuropathy (numbness/tingling in hands/feet with some drugs)
• Hair loss (depends on specific drugs)
• Low blood counts

Questions to Ask:

1. For each option, what percentage of patients experience severe (grade 3-4) side effects?
2. Which side effects are reversible vs. potentially permanent?
3. How will side effects be managed?
4. What's the impact on quality of life based on your experience with other patients?
5. Can treatment be adjusted if side effects become too difficult?

4) Treatment Options for Unresectable Residual Disease

What I Found: My knowledge base has limited specific guidance on managing residual appendiceal cancer that couldn't be completely removed during CRS-HIPEC.

General Approaches That May Be Considered: Based on broader cancer treatment principles, options might include:

1. Systemic Therapy (what you're discussing):

   • Chemotherapy
   • Targeted therapy (like Ibrance)
   • Clinical trials

2. Localized Treatments (depending on disease location):

   • Radiation therapy (for specific areas)
   • Ablation techniques (for isolated lesions)
   • Repeat surgery (rarely, if disease becomes more resectable)

3. Active Surveillance (what you've been doing):

   • Monitoring with tumor markers and imaging
   • Intervening when disease shows clear progression

Questions to Ask:

1. Are there any localized treatments (radiation, ablation) that could target the pelvic disease or hepatic artery area?
2. Are there clinical trials available for appendiceal cancer with residual disease?
3. What are the criteria for when we should start treatment vs. continue observation?
4. What's the natural history - how quickly does residual disease typically progress in cases like mine?
5. Are there any molecular tests on my tumor that might identify additional treatment options?

5) Monitoring and Decision-Making

Your Current Situation:

• Rising tumor markers
• Increasing ascites (abdominal fluid)
• These suggest disease progression, which is why your oncologist is recommending treatment

Key Considerations:

Timing of Treatment:

• You've had 4 months of observation (June to now)
• Progression indicators suggest it may be time to intervene
• Earlier treatment when disease burden is lower may be more effective

Treatment Selection Factors:

1. Your overall health - How recovered are you from the 17-hour surgery?
2. Quality of life goals - How do you balance disease control with maintaining your daily activities?
3. Disease biology - How aggressive does your tumor appear to be?
4. Evidence base - Ibrance has limited data; chemotherapy has more established (though still limited) evidence

Questions to Ask:

1. What happens if we continue observation without treatment?
2. What's the expected timeline for disease progression without treatment?
3. If we start with one option and it doesn't work, can we switch to the other?
4. Are there any biomarkers or genetic tests that could help predict which treatment might work better for me?
5. What defines "success" for each treatment option (stable disease, tumor marker reduction, symptom control)?

Summary: Evidence Gaps and Next Steps

What I Could NOT Find Specific Information About:

• Ibrance specifically for appendiceal cancer post-CRS-HIPEC
• Comparative effectiveness of different chemotherapy regimens in your situation
• Outcomes data for residual disease management after incomplete cytoreduction
• Patient experiences with these specific treatments in appendiceal cancer

What This Means for You: You're in a situation where treatment decisions must be made with limited published evidence. This makes the following especially important:

1. Get a Second Opinion: Consider consulting with an appendiceal cancer specialist or a center with high volume of peritoneal surface malignancies (like MD Anderson, UPMC, or similar centers)

2. Request the Study Data: Ask your oncologist for the published study or presentation about Ibrance in appendiceal cancer

3. Consider Molecular Testing: If not already done, comprehensive genomic profiling might identify:

   • Targetable mutations
   • Biomarkers predicting response to specific treatments
   • Clinical trial eligibility

4. Explore Clinical Trials: Given limited standard options, trials may offer access to promising new approaches

5. Multidisciplinary Discussion: Ensure your case is reviewed by a tumor board including surgical oncologists, medical oncologists, and radiologists

Recommended Resources

For Appendiceal Cancer Information:

• Appendix Cancer Pseudomyxoma Peritonei Research Foundation (ACPMP) - Patient support and research organization
• PMP Pals - Patient community with experience in appendiceal cancer and CRS-HIPEC
• NCCN Guidelines for Colon Cancer - Include some guidance on appendiceal tumors (though limited)

For Finding Specialists:

• Peritoneal Surface Oncology Group International (PSOGI) - Directory of specialized centers
• American Society of Peritoneal Surface Malignancies - Can help identify experts

Final Thoughts

Your situation—residual